Crimson Publishers Publish With Us Reprints e-Books Video articles


Perceptions in Reproductive Medicine

Andropenis® Plus Oral Therapy (Peironiemev) Versus Intralesional Verpamil in the Treatment of the Acute Phase of Peyronie’s Disease

Submission: February 22, 2018;Published: September 10, 2018

DOI: 10.31031/PRM.2018.02.000548

ISSN: 2640-9666
Volume2 Issue5


Introduction: The aim of this study was to compare the association of a POTABA based oral compound (PeironiMEV®) with a penile extender (Andropenis®) stretching protocol to Verapamil injections in the treatment of Peyronie’s disease (PD).

Materials and methods: Patients with PD naive to any treatment were enrolled and randomized: Andropenis 8 hours per day plus PeironiMEV 2 tablets/die for 6 months (arm 1); Intralesional Verapamil 5mg/2ml every two weeks for 6 months (arm 2). Patients were evaluated at 3, 6, 12 and 24 months after baseline. Plaque size, curvature degree and penile lenght were recorded at each visit during the follow-up. Functional results were assessed through: Erectile Function (EF) domain score of the International Index of Sexual Function (IIEF), Sexual Encounter Profile (SEP 2) and VAS score.

Results: 40 patients were enrolled. At 12 months, VAS and EF domains of IIEF improvement was significantly higher in arm 1 (p< 0.001). In both arms penile curvature showed a significant reduction (p< 0.001) at 12 months follow up. Penile flaccid and stretched length had a trend to improvement in arm 1 (p 0.087 and 0.078 respectively).

Conclusion: PeironiMEV plus penile stretching impacted on patient erectile function. Moreover, it demonstrated to be more effective than verapamil injections in pain control.

Keywords: Peyronie disease; Penile extender; Conservative treatments; Verapamile injection; Penile curvature

Get access to the full text of this article